Results 231 to 240 of about 106,669 (305)
Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang +4 more
wiley +1 more source
Case of Abscess at the Neck of the Bladder, Causing Retention of the Urine.
Wm B Herrick
openalex +1 more source
Background and Purpose Oxidative stress plays a critical role in the pathophysiology of various diseases, yet current methods for its non‐invasive detection remain limited. This study aimed to systematically validate a superoxide‐selective PET tracer, [18F]FPBT, for the early diagnosis and therapeutic monitoring of oxidative stress‐related conditions ...
Hua Zhang +10 more
wiley +1 more source
Tumor‐Derived Exosomal piR‐hsa‐28212 Promotes Lymphatic Metastasis in Breast Cancer
Breast cancer–derived exosomal piR‐hsa‐28212 promotes lymphangiogenesis and lymph node metastasis by activating VEGFC/VEGFR3 signaling. It stabilizes TBX1 mRNA in lymphatic endothelial cells and METTL3 protein in tumor cells, enhancing VEGFR3 expression and VEGFC secretion.
Yafen Wang +7 more
wiley +1 more source
Acute urinary retention from hyperangulation of the urinary bladder neck secondary to uterine leiomyoma, a case report. [PDF]
Poston C, Odunlami T, Hurtado E.
europepmc +1 more source
Copy number variation analysis in The Cancer Genome Atlas identified NTAQ1 as a potential driver of HCC progression. NTAQ1 accelerates tumor growth by promoting the degradation of the tumor suppressor protein PRDM2, thereby impairing DNA repair and suppressing apoptosis. These findings indicate that NTAQ1 could be a valuable target for the treatment of
Tomohiko Ikehara +21 more
wiley +1 more source
Primary bladder neck obstruction in men-new perspectives in physiopathology. [PDF]
Cash H +4 more
europepmc +1 more source
Off‐label nivolumab treatment guided by CGP results was evaluated in 56 patients with advanced solid tumors. TMB‐High was the predominant biomarker leading to nivolumab treatment. Nivolumab showed limited clinical benefit in 50 patients with measurable disease, with an ORR of 16.0%, DCR of 40.0%, median PFS of 2.7 months, and median OS of 7.2 months ...
Masashi Kanai +16 more
wiley +1 more source

